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Neurobiology of Disease

Genetic Suppression of Transgenic APP Rescues
Hypersynchronous Network Activity in a Mouse Model of
Alzeimer’s Disease
Heather A. Born,1 Ji-Yoen Kim,1 Ricky R. Savjani,1,8 Pritam Das,9 Yuri A. Dabaghian,6,10 Qinxi Guo,7 Jong W. Yoo,2
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Alzheimer’s disease (AD) is associated with an elevated risk for seizures that may be fundamentally connected to cognitive dysfunction.
Supporting this link, many mouse models for AD exhibit abnormal electroencephalogram (EEG) activity in addition to the expected
neuropathology and cognitive deficits. Here, we used a controllable transgenic system to investigate how network changes develop and
are maintained in a model characterized by amyloid ␤ (A␤) overproduction and progressive amyloid pathology. EEG recordings in tet-off
mice overexpressing amyloid precursor protein (APP) from birth display frequent sharp wave discharges (SWDs). Unexpectedly, we
found that withholding APP overexpression until adulthood substantially delayed the appearance of epileptiform activity. Together,
these findings suggest that juvenile APP overexpression altered cortical development to favor synchronized firing. Regardless of the age
at which EEG abnormalities appeared, the phenotype was dependent on continued APP overexpression and abated over several weeks
once transgene expression was suppressed. Abnormal EEG discharges were independent of plaque load and could be extinguished
without altering deposited amyloid. Selective reduction of A␤ with a ␥-secretase inhibitor has no effect on the frequency of SWDs,
indicating that another APP fragment or the full-length protein was likely responsible for maintaining EEG abnormalities. Moreover,
transgene suppression normalized the ratio of excitatory to inhibitory innervation in the cortex, whereas secretase inhibition did not. Our
results suggest that APP overexpression, and not A␤ overproduction, is responsible for EEG abnormalities in our transgenic mice and can
be rescued independently of pathology.
Key words: amyloid precursor protein; EEG; epilepsy; seizure; sharp wave discharge; transgene suppression

Introduction
A growing body of evidence suggests that Alzheimer’s disease
(AD) increases the risk for seizures above the rise connected with
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crease in seizure incidence compared with the general population, whereas early-onset familial AD is linked to an astonishing
87-fold rise (Amatniek et al., 2006). Seizure disorders and epilepsy are especially pronounced in families with presenilin mutations, in which nearly 30% of patients display this comorbidity,
rising to nearly 75% in cases of particularly aggressive variants
with onset before age 40 (Snider et al., 2005; Larner and Doran,
2006; Jayadev et al., 2010). Recent studies suggest that electrical
imbalance may contribute to cognitive deficits in AD and serve as
a target for clinical intervention (Palop and Mucke, 2009). Consistent with this idea, mouse models for AD show improved spatial navigation and diminished anxiety after treatment with the
antiepileptic drug levetiracetam (Sanchez et al., 2012). Similar
benefit from levetiracetam was observed in a small pilot study of
patients with mild cognitive impairment (Bakker et al., 2012).
The mechanism by which AD increases seizure risk has only
recently been explored using mouse models for the disease. Spontaneous seizures and sharp wave discharges (SWDs) have been
observed in several transgenic models expressing mutations in
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amyloid precursor protein (APP). The seizure phenotype is most
often noted in models carrying the Swedish mutation, including
Tg2576 (Westmark et al., 2008), APP23 (Lalonde et al., 2005),
hAPPJ20 (Palop et al., 2007; Sanchez et al., 2012; Verret et al.,
2012; Corbett et al., 2013), and APP/PS1dE9 (Minkeviciene et al.,
2009; Ziyatdinova et al., 2011). The prominent amyloid phenotype of these models has pointed to amyloid ␤ (A␤) as the mechanistic link connecting AD with seizures (Palop and Mucke,
2010). Although bath application of exogenous A␤ generally
diminishes synaptic plasticity, it conversely increases electrical
activity of excitatory neurons (Minkeviciene et al., 2009). Hippocampal neurons in transgenic APP mice display abnormal
spontaneous activity well before plaque formation (Busche et al.,
2012), with hyperactive foci persisting at the periphery of amyloid deposits in later stages of disease (Busche et al., 2008). In
turn, this hyperactivity may increase synaptic exocytosis of A␤
(Kamenetz et al., 2003; Cirrito et al., 2005; Bero et al., 2011),
placing A␤ at the center of a pathological feedback loop (Noebels,
2011).
A␤ may not be the only contributor to epileptogenesis in AD
and its mouse models. Patients with APP duplication are at
greater risk for seizure (Cabrejo et al., 2006), as are Down syndrome patients with dementia (Menéndez, 2005). Many AD
mouse models also produce high levels of APP, making it difficult
to distinguish whether A␤ is solely responsible for seizure activity
or if other APP fragments may also contribute. Moreover, unlike
most AD patients, transgenic mice overexpress APP during cortical development, when the protein’s synaptogenic properties
may have unanticipated effects on circuit connectivity (YoungPearse et al., 2008; Wang et al., 2009; Zheng and Koo, 2011).
Because of their intrinsic relationship, separating the impact of
APP from that of A␤ and amyloid has been experimentally challenging. Here, we used a controllable APP-transgenic model to
separate these factors and evaluate how APP overexpression, A␤
overproduction, and plaque formation each contribute to network hyperactivity.

Materials and Methods
Mice
We studied tetracycline-responsive APP-transgenic mice (APP/TTA) expressing a chimeric mouse APP with a humanized A␤ domain encoding
the Swedish and Indiana mutations (MMRRC #34845; Jankowsky et al.,
2005) that had been mated to CaMKII␣-tTA line B mice expressing the
tetracycline transactivator under control of the CaMKII␣ promoter
(#3010; Jackson Laboratories; Mayford et al., 1996). Single-transgenic
(TTA only) and nontransgenic (NTG) cagemates were used as controls.
Each line had been independently backcrossed to C57BL/6J for ⬎20
generations before being intercrossed to generate stud males that were
bred with C57BL/6J females to generate animals for study (Rodgers et al.,
2012). Animals were housed on a 12 h/12 h or 13 h/11 h day/night cycle
and were used for study between 3 and 12 months of age.
APP/PS1 double knock-in mice were created by crossing APP
knock-in mice encoding a humanized A␤ domain flanked by the Swedish
and London mutations with PS1 knock-in mice encoding the M146V
mutation (Guo et al., 1999; Köhler et al., 2005). Both lines were maintained on a C57BL/6 J background and were 23–24 months of age at the
time of study. All studies were gender balanced. All animal experiments
were performed using protocols that were reviewed and approved by the
Institutional Care and Use Committee at Baylor College of Medicine.

Chronic EEG recording and analysis
Direct EEG recording. One cohort of APP/TTA, TTA, and NTG mice were
implanted for baseline EEG recordings using wired, two-lead subdural
EEG. After anesthesia with Avertin, subdural recording electrodes were
implanted bilaterally over the parietal cortices. Mice were allowed to

J. Neurosci., March 12, 2014 • 34(11):3826 –3840 • 3827

recover for at least 24 h before recording. EEG signal was recorded over 3
3 h sessions using the Stellate Harmonie system (Natus Medical). Data
were sampled at 200 Hz over a frequency range of 0.3–70 Hz. Recordings
were analyzed manually for SWDs and seizures by a blinded observer.
Estimating the specificity and sensitivity of single-lead EEG recordings.
For the semiquantitative experiments we had in mind, we needed an EEG
system that would deliver high-throughput, chronic recording capability. Telemetric recording systems provided these advantages, but at the
cost of spatial resolution: mouse-sized radiofrequency transmitters carried only one recording lead rather than the two or more used by traditional EEG equipment. To validate the accuracy of EEG data obtained
from a single lead, we reanalyzed the recordings made with our dual-lead
wired setup to count the number of SWDs detected by one lead against
the number detected by both. This provided a rough estimate of the
percentage of bilateral events that would be accurately detected by a
single recording electrode, along with a measure of the number of false
positives that would be detected in a single lead but not present bilaterally. We found that, as the number of SWDs increased, so also did the
percentage of SWDs recorded bilaterally, such that for data beyond ⬃30
spikes/h, ⬎90% of all spikes identified by one electrode were seen in both
(Fig. 1). Because most of our APP/TTA recordings fell at or above this
SWD frequency, we transitioned to telemetry for all subsequent EEG
recordings.
Telemetric EEG and locomotor recording. All subsequent EEG experiments used wireless ETA-F10 transmitters (Data Sciences International)
for chronic EEG recording and locomotor monitoring. After anesthesia
with isoflurane, a 1 cm midline sagittal incision was made starting above
the interaural line and extending along the neck to create a pocket for
subcutaneous placement of the transmitter along the dorsal flank of the
animal. The recording electrode (stereotaxic coordinates relative to bregma: ⫹2.5 mm, ⫺2.5 mm) and ground electrode (⫺1.0 mm, ⫹1.0 mm)
were implanted subdurally through small holes drilled in the skull and
held in place with dental cement. Mice were provided with ketoprofen
analgesic for 3 d after surgery and allowed to recover for 10 d before
recording.
Mice remained in their home cage during overnight recording sessions. EEG signal was collected through radiofrequency receivers placed
under each cage. Locomotor activity was also interpolated from this
signal by monitoring changes in signal strength between the transmitter
and receiver as the animal moved about the cage. Using this system, a
movement count was triggered whenever the signal change exceeded a
prespecified threshold. Locomotor data are therefore reported as arbitrary activity counts per hour. Locomotor data were acquired at a sampling rate of 16 Hz; EEG data between 1 and 200 Hz were acquired at a
sampling rate of 1 kHz using the Dataquest A.R.T. system, versions 2.1
and 4.0 (Data Sciences International).
Automated EEG analysis. Three overnight recordings made over the
course of a week were averaged to determine the baseline frequency of
SWDs per hour for each mouse. EEG recordings were analyzed to include
a balanced number of daylight and nighttime hours for a total of 12 h per
session (from 3:00 to 9:00 A.M. and from 4:00 to 10:00 P.M.). EEG signal
was filtered using a band pass of 0.3–70 Hz. Automated analysis of SWDs
was done using Neuroscore software version 2.1 (Data Science International). The baseline threshold for each recording was manually determined as the best fit line that includes the majority of the EEG trace using
the period between 12:00 and 1:00 A.M. when a low frequency of SWDs
was observed. To be counted as a SWD, an electrical event must be brief
in duration (5–15 ms) and have a peak amplitude 2.5⫻ greater than the
average baseline range. The ETA-F10 transmitters also acquired data on
animal movement during recording, which was analyzed using Neuroscore to report activity counts per hour.

Power, entropy, and autocorrelation analyses
Two time points were analyzed for each animal, once before (baseline)
and once after 4 weeks of transgene suppression. Analysis of each condition was limited to data collected during a single 6 h session spanning 1
dark-light transition (3:00 –9:00 A.M.). Data were not filtered before
analysis. One animal was excluded from each genotype due to noise in

Born et al. • APP Suppression Rescues EEG Abnormalities

3828 • J. Neurosci., March 12, 2014 • 34(11):3826 –3840

Figure 1. EEG recording reveals abnormal SWDs in tet-off APP-transgenic mice. A, B, EEG recordings made via wired dual-lead electrodes (A) or by wireless radiofrequency transmitters (B)
uncovered frequent SWDs and irregular seizure episodes in APP/TTA mice. Scale bars: A, 0.5 mV and 2 s; B, 0.4 mV and 2 s. C, Recordings made with dual-lead electrodes were used to assess the
percentage of spikes that would be counted in error by moving to a single-lead setup. The graph illustrates the percentage of SWDs recorded bilaterally as a function of SWDs recorded unilaterally.
As the number of spikes increased, so also did the percentage of spikes recorded bilaterally. One data point (circled) was identified as an outlier and excluded from analysis. D, APP/TTA mice display
a significantly higher number of SWDs/h than age-matched NTG and TTA controls. ***p ⬍ 0.001. E, SWD frequency was inversely related to locomotor activity in APP/TTA mice. Black circles, SWDs;
open circles, locomotor activity.

the signal that invalidated full-spectrum analyses, but this did not affect
measurement of large-amplitude SWDs.
To characterize the spectral properties of the EEG signal in the WT and
AD mice, we first normalized each signal by its SD and then computed
the Fourier transform for each recording with an 8 s (8000 points) time
window using the standard MATLAB Signal Processing toolbox (MathWorks). We calculated the normalized signal amplitude as a function of
frequency between 0 and 300 Hz across the entire 6 h window. The results
were then averaged for control and APP/TTA groups with no additional
smoothing. Because the data were normalized before transformation,
values are expressed as arbitrary units rather than mV 2.
To characterize the entropy of peak timing in the EEG signal, we first
isolated peak values ⬎3 SD of the mean signal amplitude. These points
were characterized by the time at which they occurred in the recording

and used to calculate nearest-neighbor interpeak intervals. We next performed a sliding analysis of the data using a 17 s (17,000 points) window
at a time. For each window, we plotted the distribution of interpeak
intervals and from this calculated the entropy of the distribution according to the following equation:

H⫽ ⫺

冘
x

P 共 x 兲 log2 P共 x兲,

The window was then shifted by 0.1 s (100 points) and the entropies
recomputed. By scanning the entire time axis in this way, we obtained
entropy as a function of time. The results were averaged for each genotype and used to compute the entropy distributions shown in Figure 3.
Both the amplitude threshold for defining signal peaks and the time
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window used for scanning the data were tested at multiple values and
yielded similar results to the 3 SD/17 s analysis shown here.
Autocorrelation within the signal was tested for time lags ranging from
0 to 10 s (10,000 points) using MATLAB Signal Processing and Econometrics toolboxes. Group averages at each time lag were calculated and
graphed as mean and SE.

capture (human A␤x-42 specific) and HRP-conjugated monoclonal antibody Ab9 (human A␤1–16 specific) for detection or monoclonal antibody Ab9 for capture and HRP-conjugated monoclonal antibody 13.1.1
(human A␤x-40 specific) for detection (Levites et al., 2006a; Levites et al.,
2006b). All values were calculated as picomoles per gram based on the
initial weight of brain tissue.

Doxycycline treatment

Seizure induction

To measure the effect of transgenic APP suppression on SWD frequency,
one cohort of mice was treated with doxycycline (DOX) for 4 –5 weeks
after completion of baseline EEG recordings (F5903 50 mg/kg DOX in
TestDiet 5001 rodent chow; Purina).
A separate cohort of animals was used to measure the effect of delaying
transgenic APP expression until adulthood on EEG activity. Mice used
for adult onset studies were reared on DOX chow to suppress APP overexpression for the first 6 weeks of life, as described previously (Rodgers et
al., 2012). At 6 weeks of age, mice were returned to unmedicated chow to
initiate expression of transgenic APP. Thereafter, the transgene was continuously expressed until EEG testing.

In vivo microdialysis

The effect of DOX treatment on soluble A␤ levels was determined using
a separate cohort of mice implanted for microdialysis of interstitial fluid
(ISF). Mice were unilaterally implanted with a 38 kDa MW cutoff microdialysis probe (2 mm BR-style; Bioanalytical Systems) placing the probe
tip into the hippocampus at a 12 degree angle ⫺3.1 mm from bregma,
⫺2.5 mm from midline, and 3.2 mm below the dura (Cirrito et al., 2003;
Cirrito et al., 2011). Microdialysis perfusion buffer consisted of 4% albumin in artificial CSF at a flow rate of 1.0 l/min. Animals were allowed to
recover for 6 – 8 h after probe insertion, and then 6 ISF A␤ measurements
were taken over a 6 h period. The mean concentration of exchangeable
A␤ during this 6 h period was defined as the baseline ISF A␤ concentration for each mouse. After basal A␤ levels were determined, mice were
administered DOX through their chow as above and microdialysis samples were taken into a refrigerated fraction collector every 1–3 h for the
following 4 d. After the final collection, samples were assayed for A␤x-40
and A␤x-42 by sandwich ELISA using an A␤40 (mHF2)- or A␤42-specific
antibody (mHJ7.4) to capture the peptide, followed by a biotinylated
central domain anti-A␤ antibody (mHJ5.1) for detection (Cirrito et al.,
2011). The concentration of ISF A␤ in each sample was normalized to the
baseline A␤ concentration for each mouse. At the end of the experiment,
the brains were harvested and processed for histological verification of
probe placement.

␥-Secretase inhibition

To test the efficacy of ␥-secretase inhibition on steady-state levels of A␤
in our mice, we administered young, predeposit APP/TTA mice (5– 6
weeks of age) either a single intraperitoneal dose of LY411575 or 1 week
of medicated chow. For acute treatment, the drug was dissolved in
DMSO at 100 mg/ml, diluted in corn oil to the appropriate concentration, and injected intraperitoneally to deliver 0, 2.5, 5, 10, or 20 mg/kg.
Mice were harvested 3– 4 h after injection. Dosing for subchronic treatment was assessed by feeding mice chow compounded with LY411575 at
50 mg/kg to deliver 5 or 10 mg/kg/d. Mice were harvested after 1 week of
treatment. From these dose–response studies, we decided to use a stepdown regimen in the aged cohort to test the effect of ␥-secretase inhibition on EEG activity. After baseline recordings, aged APP/TTA and
control mice were treated for 2 weeks with LY411575 compounded at a
concentration of 50 mg/kg into Purina TestDiet 5001 chow to deliver 10
mg/kg/d. After 2 weeks of treatment at 10 mg/kg/d, dosing was decreased
to 5 mg/kg/d for the remainder of the experiment.

A␤ ELISA

To measure the dose response of LY411575 on soluble A␤ levels, tissue
was harvested from mice treated acutely or subchronically with
LY411575 as described in ␥-Secretase inhibition, above. Frozen hemiforebrain samples were homogenized by sonication in 7.5 volumes of
TBS containing 1% Triton X-100 and 1⫻ protease inhibitor mixture as
described previously (Jankowsky et al., 2007). A␤ levels were determined
by end-specific sandwich ELISAs using monoclonal antibody 2.1.3 for

To determine whether APP overexpression altered the threshold for
chemical seizure induction, mice were implanted with ETA-F10 transponders as described in Telemetric EEG and locomotor recording,
above and recorded for pretreatment values before convulsant exposure.
Picrotoxin (P1675; Sigma) was dissolved in sterile saline and injected
subcutaneously at 1.75 mg/kg. Mice were videotaped during EEG recording for 1 h after injection. A separate cohort of mice was treated with
kainic acid (BML-EA123; VWR) injected subcutaneously at 35 mg/kg
and recorded for 1 h after injection. Video recordings were reviewed to
determine: (1) the latency to seizure onset, (2) the total number of seizures induced, and (3) the severity of each seizure. Behavioral changes
were scored according to the Racine scale, with 0 ⫽ normal activity; 1 ⫽
hypoactivity; 2 ⫽ head or forelimb clonus; 3 ⫽ whole-body clonus, rearing and falling, or wild running; 4 ⫽ tonic-clonic seizures; and 5 ⫽ death
(Racine, 1972; Ferraro et al., 1999). EEG recordings were analyzed for
latency to onset and number of seizures.

Tissue harvest
Animals were killed at the end of each experiment and brain tissue was
collected through one of two methods. For the first method, one hemisphere was frozen for biochemical analyses and the other hemisphere was
immersion fixed for 48 h at 4°C in 4% paraformaldehyde/1⫻ PBS. For
the second method, mice were transcardially perfused with PBS containing 10 U/ml heparin followed by 4% paraformaldehyde/1⫻ PBS and
postfixed for 24 h at 4°C in 4% paraformaldehyde/1⫻ PBS.

Immunoblotting
Frozen hemi-forebrain or cortical tissue was homogenized by sonication
in 7.5 volumes of 2% SDS and then diluted with an equal volume of
2⫻-concentrated RIPA buffer minus SDS (2⫻ PBS, 1% deoxycholate,
1% NP40, 5 mM EDTA, plus protease inhibitors) to yield a 6.7% homogenate in 1⫻ RIPA buffer. Approximately 35 g of protein from this
homogenate was separated using 10.5–14% Tris-glycine gels (Bio-Rad)
for quantitation of protein levels. After transfer to nitrocellulose (iBlot;
Invitrogen), blots were blocked for 1 h in 5% nonfat dry milk before
being incubated with one or more primary antibodies: mouse antihuman APP/A␤ antibody 6E10 (catalog #9300-02, 1:5000; Signet), rabbit
anti-CT15 (1:4000; a gift from Eddie Koo). Chicken anti-GAPDH polyclonal antibody (catalog #Ab2302, 1:5000; Millipore) was used as a loading control. Binding was detected with HRP-labeled secondary
antibodies and developed with ECL reagent (Millipore). Chemiluminescence was measured with a Fuji LAS-4000 mini CCD system and quantified using MultiGauge software.

Histology
Immersion-fixed hemibrains were cryoprotected with 30% sucrose at
4°C before being frozen and sectioned at 35 m using a freezing sliding
microtome. Sections were stored in cryoprotectant at ⫺20°C until use.
Campbell–Switzer silver stain. Amyloid was detected from a 1 in 24
series of sections using the Campbell–Switzer silver stain. A detailed
protocol for this stain can be found online at the NeuroScience Associates
website (http://www.neuroscienceassociates.com/Documents/Publications/
campbell-switzer_protocol.htm).
A␤ immunohistochemistry. A 1 in 24 series of sections was pretreated
with 88% formic acid for 1 min at room temperature, rinsed several times
with TBS, and blocked with TBS plus 0.1% Triton-X (TBST) containing
1.5% normal goat serum before being incubated overnight at 4°C with
rabbit anti-APP/A␤ antibody diluted in blocking solution (catalog #44344, 1:500; Zymed). After washing with TBS, sections were incubated for
1 h with biotin-conjugated goat anti-rabbit secondary antibody (Vectastain Elite Rabbit IgG ABC Kit, 1:500; Vector Laboratories), followed
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by HRP-avidin conjugate diluted 1:100 in TBS for 30 min, and then
developed with DAB.
Vesicular glutamate transporter 1/vesicular GABA transporter immunofluorescence. Sections were rinsed with TBS to remove antifreeze and
blocked with TBS plus 0.1% Triton X-100 containing 5% normal goat
serum followed by overnight incubation at 4°C in primary antibody
diluted in blocking solution (rabbit antivesicular glutamate transporter 1
[vGLUT1], catalog #135-303, 1:2000; Synaptic Systems and guinea pig
antivesicular GABA transporter [vGAT], catalog #131-004, 1:750; Synaptic Systems). After washes with TBS, sections were incubated with
Alexa Fluor 488-conjugated goat anti-rabbit antibody (catalog #A11034,
1:500; Invitrogen) and Alexa Fluor 594-conjugated goat anti-guinea pig
antibodies (catalog #A11076, 1:750; Invitrogen).
Quantification of vGLUT1/vGAT. Sagittal sections located ⬃1–1.5 mm
from midline were selected for analysis based on landmarks in hippocampus, lateral ventricle, and striatum. A total of 4 –5 sections were
imaged per animal. Fluorescent images were collected from nonoverlapping fields within cortex (L2/3 above CA1 and L5 above lateral ventricle).
A single optical plane of 0.977 m in depth was collected in red (vGAT)
and green (vGLUT) channels using an ApoTome structured illumination
device (Carl Zeiss) at 40⫻ magnification (222.2 ⫻ 166.4 m per field).
We used a custom script written in MATLAB (R2012b) to batch process
two-channel fluorescence images in an unbiased and automated way.
Grayscale images were binarized using Otsu’s method to divide the dataset into signal and background so that the variance in each of the
resulting subsets is mimimized. In this case, the method uses variance
minimization to define the cutoff between immunopositive pixels and
background. The script then calculates the area occupied by vGLUT- or
vGAT-positive pixels in each image normalized to the total area of the
field. We have posted a modified version of the script on MATLAB’s file
exchange site (http://www.mathworks.com/matlabcentral/fileexchange/
39591).

Statistics
EEG power, entropy, and autocorrelation analyses were analyzed by
repeated-measures ANOVA using MATLAB; reported p-values represent the main effect of genotype. All other statistical analyses were done
using GraphPad Prism 5.0. Comparisons between two groups were analyzed using Student’s t test. Comparisons involving more than two
groups were analyzed using one-way or two-way ANOVA followed by
Bonferroni post hoc tests. Unless indicated (and with the exception of
power, entropy, and autocorrelation analyses), all reported p-values are
for post hoc comparisons. All graphs display group mean ⫾ SEM.

Results
Tet-off APP mice display EEG abnormalities similar to other
APP-transgenic models
A growing number of studies have documented abnormal electrical activity in APP-transgenic models for Alzheimer’s disease
(Lalonde et al., 2005; Palop et al., 2007; Westmark et al., 2008;
Minkeviciene et al., 2009; Ziyatdinova et al., 2011; Sanchez et al.,
2012; Verret et al., 2012; Corbett et al., 2013). These models differ
in the APP mutations they encode, the coexpressed transgenes,
and the promoters used to drive expression. We were therefore
optimistic that their shared APP overexpression is salient to the
EEG phenotype and that we might also find EEG abnormalities in
our tetracycline-controllable APP-transgenic mice. These mice
express mouse APP with a humanized A␤ domain harboring the
Swedish and Indiana familial mutations (tetO-APP line 102) under control of the CaMKII␣-TTA driver (APP/TTA; Jankowsky
et al., 2005). We used traditional wire-lead EEG recordings (Stellate Systems) to measure electrical activity in the brains of bigenic
APP/TTA animals and their single-transgenic and NTG siblings
at an age when we knew the bigenic mice would harbor amyloid
pathology (7–9 months). As described for other APP-transgenic
models, we detected frequent SWDs and irregular seizure episodes in the APP/TTA mice (19/21 exhibit ⬎30 SWDs/h),
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whereas both of these features were absent from traces recorded
in controls (0/15 mice exhibit ⬎30 SWDs/h; Fig. 1).
Although wired EEG recordings are the gold standard for localizing the origin and spread of seizure activity, our system was
limited in throughput. To conduct a quantitative analysis of EEG
abnormalities in our model and then follow their response to
various interventions, we moved to a wireless radiofrequency
telemetry system that enabled us to perform continuous homecage EEG recordings from up to eight mice at a time. Consistent
with the qualitative observation from wired EEG recordings,
quantitative analysis of wireless telemetry sessions confirmed
that APP/TTA mice display a significantly higher number of
SWDs/h than age-matched NTG and TTA controls (NTG ⫽
6.24 ⫾ 0.62; TTA ⫽ 7.84 ⫾ 1.12, APP/TTA ⫽ 125.40 ⫾ 16.62,
p ⬍ 0.001, n ⫽ 4 –11 mice/genotype; Fig. 1). We found no differences in the EEG properties of NTG and TTA mice and decided to
combine both genotypes into balanced control groups for subsequent experiments.
We also assessed locomotor activity during our EEG sessions
using information collected by the telemetry device. We found an
inverse correlation between SWD frequency and ambulation
such that SWD frequency was highest during daylight hours,
when the mice are the least physically active and more likely to be
asleep (Fig. 1).
Genetic suppression of transgenic APP normalizes cortical
EEG activity
One advantage of using the tet-off APP model is that we can
exercise temporal control over transgenic APP expression using
orally administered DOX. Transgene expression can be reduced
by ⬎90% using moderate doses of DOX compounded into the
chow (Jankowsky et al., 2005; Wang et al., 2011; Rodgers et al.,
2012). In the present experiments, chow provided by a different
vendor was slightly less effective but still reduced transgenic APP
levels by ⬃80%. Transgenic APP was reduced by 77 ⫾ 0.09%
within 2 d of DOX administration and remained at 82 ⫾ 0.02%
suppression 4 weeks later (n ⫽ 3–5 mice/time point; Fig. 2). We
next performed in vivo microdialysis of hippocampal interstitial fluid to confirm that A␤ levels declined in parallel with
transgenic APP expression. Baseline levels of A␤40 and A␤42
were 231.1 ⫾ 30.1 pg/ml and 25.42 ⫾ 3.7 pg/ml, respectively
(n ⫽ 5), but dropped by nearly half to 48.0 ⫾ 5.4% (A␤40) and
55.6 ⫾ 5.3% (A␤42) within 2 d after the mice began DOX
treatment (Fig. 2). We suspect that compensatory release of
exchangeable A␤ from nearby amyloid plaques may have limited the reduction of interstitial A␤ relative to full-length APP
(Hong et al., 2011). Nonetheless, both transgenic APP and
transgene-derived A␤ were significantly decreased within 2 d
of DOX treatment. Despite the significant reduction in A␤
release, amyloid load was unchanged by DOX treatment. We
have used this model in past studies to demonstrate that transgene suppression arrests amyloid growth indefinitely
(Jankowsky et al., 2005; Wang et al., 2011). Plaque load neither
progresses nor abates, so DOX treatment provides a way of
reducing transgenic APP and soluble/exchangeable forms of
A␤ without altering deposited amyloid.
Once baseline EEG recordings were completed, we
switched all of the mice to DOX chow and continued weekly
EEG recordings for another 4 –5 weeks (Fig. 2). We found that
SWD frequency steadily decreased in the APP/TTA mice, but
over a time frame considerably longer than that of transgene
suppression. After 2 weeks of DOX treatment, the SWD frequency in APP/TTA mice was significantly lower than baseline
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Figure 2. Transgene suppression reduces the frequency of SWDs in APP/TTA mice. A, Mice were implanted with radiofrequency transmitters at 7– 8 months of age. After baseline recordings were
completed, all mice were treated with DOX while continuing weekly EEG recordings. B, C, Western blotting for transgenic APP (6E10) confirmed that untreated APP/TTA mice expressed high levels
of transgenic protein. Expression was substantially decreased within 2 d of DOX treatment and remained low at the end of the experiment 4 –5 weeks later. D, Quantification of the Western blots
shown in B and C. Transgenic APP has been normalized to GAPDH and all values are expressed relative to baseline expression in untreated bigenic animals. ***p ⬍ 0.001. E, In vivo microdialysis
showed that ISF A␤ reached new steady-state levels within days after transgene suppression. Black circles, A␤40; gray circles, A␤42. F, Tissue sections immunostained for A␤ confirmed that plaque
loads were similar in untreated and DOX-treated APP/TTA mice used for EEG analysis. G, EEG abnormalities in APP/TTA mice were substantially reduced after 4 weeks of transgene suppression. Scale
bar, 0.4 mV, 5 s. H, Comparison of SWD frequency over time in APP/TTA mice before and after 4 weeks of transgene suppression revealed that the decrease in SWD frequency was most pronounced
during daylight hours. Filled circles, baseline; open circles, DOX 4 weeks. I, Rate of SWDs in APP/TTA mice declined steadily from the start of treatment and became statistically indistinguishable from
controls after 4 weeks of transgene suppression. Black circles, APP/TTA; gray circles, Control. **p ⬍ 0.01, ***p ⬍ 0.001 vs Control; †p ⬍ 0.05, ††p ⬍ 0.01, †††p ⬍ 0.001 vs Baseline. J, Locomotor
activity measured during EEG recordings suggests that nighttime movement is slightly diminished in both genotypes by DOX treatment. Circles, APP/TTA; squares, Control; filled symbols, Baseline;
open symbols, DOX 4 weeks.
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(baseline: 125.4 ⫾ 16.6; DOX 2 weeks:
68.7 ⫾ 15.6 SWDs/h; p ⬍ 0.05; n ⫽ 11
mice). After 4 weeks of DOX treatment,
the frequency of SWD in APP/TTA mice
was statistically indistinguishable from
controls (DOX 4 weeks, APP/TTA:
43.9 ⫾ 5.6; Control: 11.5 ⫾ 2.7 SWDs/h;
DOX 5 weeks, APP/TTA: 29.9 ⫾ 12.7;
Control: 12.1 ⫾ 4.3 SWDs/h, p ⬎ 0.05,
n ⫽ 9 –11 mice/genotype). The change
was most apparent during daylight
hours, when SWD frequency was highest in the untreated mice. In contrast,
the rate of SWDs in our control group (a
balanced mix of NTG and TTA) was already low at baseline and did not change
with DOX treatment.
The presence of SWDs is just one feature of the EEG signal that distinguishes
APP-transgenic mice from controls. Past
studies have shown significant irregularities in the power spectrum of EEG signals
from APP-transgenic animals, noting that
a subset of mice display dramatic changes
in amplitude at selected wavelengths
(Verret et al., 2012). We were particularly
keen to determine whether similar differences existed in the APP/TTA mice and, if
so, whether they were normalized by
transgene suppression. We examined
three features of the EEG signals that
broadly defined their underlying structure: (1) the power spectrum across wavelengths, (2) the entropy of interpeak
intervals, and (3) signal autocorrelation.
In agreement with past studies, we found Figure 3. Transgene suppression normalizes the power spectrum, entropy, and autocorrelation of EEG signal in APP/TTA mice.
that the power spectrum differed signifi- A, Spectral analysis of the EEG signal revealed a shift toward higher power in the theta range and diminished power in the delta
cantly between genotypes during baseline range of untreated APP/TTA mice compared with controls. After 4 weeks of transgene suppression, the power distribution was
identical between genotypes. B, Interpeak timing in untreated APP/TTA mice has a lower entropy distribution compared with
recordings. Power curves from APP/TTA control mice, suggesting that their electrical activity is less stochastic than normal. The entropy distribution returns to control levels
and control mice were readily distin- after 4 weeks of transgene suppression. C, Autocorrelation within the EEG signal is lower in untreated APP/TTA mice than controls,
guished by their profiles and their peaks. indicating that the signal is intrinsically more structured. This, too, returns to control levels after DOX treatment. Red, APP/TTA;
Although control animals displayed blue, Control.
peak power levels in the delta range
(2.6 –3.8 Hz, peak at 3.1, n ⫽ 8), the
ization, we found that the entropy of peak timing in baseline
spectra of APP/TTA mice reached maximal power at frequenrecordings from APP/TTA was significantly lower than in control
cies in the theta range (5.9 – 8.5 Hz, peak at 7.6; n ⫽ 10) and the
mice. Although the absolute numbers are immaterial (they vary
overall distribution of the two groups was significantly differwith the peak threshold and time window used to measure interent ( p ⫽ 0.014, Fig. 3). In contrast, the power spectra after
peak intervals), the overall shape of the entropy probability
DOX treatment were nearly indistinguishable ( p ⫽ 0.62).
distribution for untreated APP/TTA mice was much lower and
Both groups had peak power levels in the delta to low theta
broader than the corresponding control values ( p ⫽ 0.033;
range (Control: 2.2– 6.8 Hz, APP/TTA: 2.6 – 6.8 Hz). TransFig. 3). This finding was supported by characterization of augene suppression thus rebalanced the power of the EEG signal
tocorrelation in the signal, which provides another way of
across the entire range of frequencies.
detecting regular structure in complex data. At short time lags,
EEG signals reveal a continuous ebb and flow of neuronal
the signal from untreated APP/TTA mice showed a greater
activity that occurs at a level far below overt SWD. The amplitude
degree of negative autocorrelation than controls ( p ⫽ 0.021;
of “chatter” in the signal rises and falls hundreds or thousands of
Fig. 3). In other words, the EEG amplitude could be more
times each minute in both healthy controls and transgenic anipredictably expected to increase within 50 –100 ms after it had
mals. Under normal conditions, these movements approximate
fallen (and vice versa) in APP/TTA mice than in controls.
random variation with little or no periodicity to the signal. This
However, both entropy and autocorrelation returned to concharacteristic is mathematically defined by its entropy. EEG sigtrol levels after 4 weeks of transgene suppression ( p ⫽ 0.48 and
nals with regular, repeating patterns have lower entropy than
p ⫽ 0.32, respectively). These findings indicate that the EEG
signals that vary randomly, reflecting a higher degree of rhythmic
synchronization in the network. Consistent with this characterabnormalities observed in untreated APP/TTA mice were de-
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Figure 4. Selective A␤ reduction does not diminish SWD frequency in APP/TTA mice. A, Mice were implanted at 8 –9 months for baseline EEG recordings before GSI treatment with continued
weekly recordings. B, EEG recordings made before and during GSI treatment show that SWDs in APP/TTA mice were unchanged after 4 weeks of selective A␤ reduction. Scale bar, 0.4 mV, 5 s. C, EEG
analysis confirmed that the rate of SWDs in APP/TTA mice did not change during treatment and remained statistically different from controls after 6 weeks of GSI treatment. Black, APP/TTA; gray,
Controls. *p ⬍ 0.05, **p ⬍ 0.01, ***p ⬍ 0.001. D, Dose–response analysis for LY411575 in young, predeposit APP/TTA mice revealed that both acute and chronic treatment reduced A␤ levels in
the brain. **p ⬍ 0.01, ***p ⬍ 0.001. E, Western blotting with 6E10 shows that expression of full-length transgenic APP is maintained during GSI treatment, however, the levels of C-terminal
fragment (CTF) increase as expected after ␥-secretase inhibition. F, Analysis of SWD frequency over time reveals that the circadian pattern of EEG activity in APP/TTA mice was unchanged by GSI
treatment. Filled circles, Baseline; open circles, GSI 4 weeks. G, Locomotor hyperactivity was also unchanged by GSI treatment. Circles, APP/TTA; squares, Control; filled symbols, Baseline; open
symbols, GSI 4 weeks.

pendent on continued expression of transgenic APP, but were
independent of deposited amyloid.

␥-Secretase inhibitor treatment does not rescue EEG
abnormalities in tet-off APP mice
The rescue of EEG abnormalities by transgene suppression suggested that either APP itself or one of its cleavage products was
responsible for establishing aberrant hyperexcitability in our tetoff APP mice. Based on its proposed role in Alzheimer’s disease,
we initially suspected that A␤ provoked this cortical hyperactivity. To test whether reducing A␤ would be sufficient to attenuate
EEG abnormalities, we treated mice with a potent ␥-secretase
inhibitor (GSI), LY411575, which selectively decreased A␤ production without affecting full-length APP expression. We first
measured the dose–response curve for this drug using brain A␤
levels as a readout of efficacy. We treated predeposit APP/TTA

mice (5 weeks of age, n ⫽ 4 – 6 per dose) with a single intraperitoneal injection of 0, 2.5, 5, 10, or 20 mg/kg and harvested 3– 4 h
later. A second group of mice was chronically treated for 1 week
by compounding the drug into chow at concentrations that
would deliver 5 or 10 mg/kg/d orally. The reduction in steadystate A␤ levels attained by acute dosing suggested that maximal
efficacy was reached by 2.5 mg/kg; however, the A␤ levels measured after 1 week of chronic treatment suggested that 10 mg/
kg/d achieved slightly better reduction for A␤42 than 5 mg/kg/d
(Fig. 4).
With information gained from this initial dosing study, we
began baseline EEG recordings in a new cohort of 8- to 9-monthold mice before beginning treatment with LY411575. We treated
the mice with chow formulated to provide 10 mg/kg/d for the first
2 weeks of treatment, followed by 5 mg/kg/d to reduce mortality
for an additional 4 weeks. To our surprise, we found no apparent
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differences in SWD frequency during GSI
treatment. Unlike what we had observed
after transgene suppression, the number
of SWDs/h remained stable in GSI-treated
APP/TTA mice over successive weeks of
recording ( p ⬎ 0.05, n ⫽ 8 –10; Fig. 4).
Neither the circadian pattern of SWDs
nor locomotor hyperactivity was altered
after 4 weeks of GSI treatment. Even after
6 weeks of GSI treatment, SWD frequency
remained identical to baseline ( p ⬎ 0.05,
Student’s t test). Similarly, sibling controls showed no difference from baseline
throughout the 6 week GSI treatment
( p ⬎ 0.05, n ⫽ 3– 6/time point). During
treatment, all of the mice developed side
effects characteristic of GSI treatment, in- Figure 5. APP/PS1 DKI mice show normal EEG activity despite elevated A␤ production. A, APPSwe/Lon/PS1M146V mice and
age-matched WT animals were implanted with transmitters for EEG recording at 23–24 months of age. B, SWDs are not evident in
cluding changes in pigmentation and aged DKI animals. Scale bar, 0.4 mV, 5 s. C, Silver histology indicates that early amyloid pathology was present by the time of EEG
patchy hair loss. After harvesting the mice, recording.
we confirmed that the dose of GSI we used
was adequate to dramatically increase
Westmark et al., 2008). We implanted APP/TTA and control
APP C-terminal fragments, suggesting that it had reached theraanimals with transmitters at 6 –7 months of age to monitor the
peutic levels in the brain. We conclude that GSI was sufficient to
seizure induction both electrographically and behaviorally. We
significantly reduce A␤ production, but failed to rescue EEG abmeasured the time to seizure onset, the number of seizures
normalities and locomotor hyperactivity. Contrary to our initial
evoked, and the behavioral severity using a modified Racine scale
expectations, these data suggest that APP itself or a fragment
(Racine, 1972; Ferraro et al., 1999). We began by testing suscepother than A␤ is responsible for EEG abnormalities in the tet-off
tibility to the noncompetitive GABAA antagonist picrotoxin,
APP mice.
which has a similar mechanism of action as pentylenetetrazol, the
agent most commonly used in past studies with APP-transgenic
Overproduction of A␤ is not sufficient to generate EEG
mice. We determined that 1.75 mg/kg subcutaneously was just
abnormalities in double knock-in APP/PS1 mice
below the threshold for convulsive seizures in NTG animals, so
As a counterpoint to GSI treatment, which selectively suppresses
we used this dose for EEG/behavioral studies in APP/TTA mice.
A␤ overproduction while maintaining APP overexpression, we
The APP/TTA mice showed a significantly stronger response to
recorded EEGs from mice that have elevated levels of A␤ with
picrotoxin than control animals for all measures we evaluated
endogenous levels of APP expression. We implanted EEG trans( p ⬍ 0.05, Student’s t test, n ⫽ 6 mice/genotype; Fig. 6). Control
mitters in homozygous APPSwe/Lon/PS1M146V double knock-in
animals
developed modest EEG abnormalities in response to pi(DKI) mice and their WT siblings at 23–24 months of age and
crotoxin,
but no electrographic seizures and only mild behavioral
recorded EEG activity during 7 sessions over 2 weeks (Fig. 5).
effects such as a flattened posture or prolonged immobility. In
This model displays early behavioral alterations (2–3 months)
contrast, all of the APP/TTA mice progressed to tonic-clonic seibut fairly late amyloid deposition, with initial plaques apparent
zures within an hour, suggesting that they have an impairment in
between 18 and 22 months of age (Guo et al., 2012; Guo et al.,
GABAergic inhibition.
2013). Although we recorded twice as many baseline sessions for
We then tested whether this heightened susceptibility exthe DKI mice as we had for the tet-off APP mice, we observed no
tended to other convulsants with different mechanisms of action.
EEG abnormalities and no increase in SWD frequency from conWe selected kainic acid as a well studied agonist of ionotropic
trols (WT ⫽ 1.18 ⫾ 0.17; DKI ⫽ 2.34 ⫾ 0.69 SWDs/h, p ⬎ 0.05,
glutamate receptors and a good counterpoint to our experiments
Student’s t test with Welch’s correction, n ⫽ 4 –5/genotype). We
with picrotoxin. We determined that 35 mg/kg was just below the
harvested the mice after recording to ascertain the presence of
convulsive dose for kainic acid in NTG controls. To our surprise,
amyloid pathology expected from this model by 24 months of
APP/TTA transgenic animals were no more susceptible to kainic
age. Although the plaque burden was considerably lower than in
acid than controls ( p ⬎ 0.05, Student’s t test, n ⫽ 5 mice/genothe tet-off APP mice, silver-positive plaques were detected in the
type; Fig. 6). Kainate induced electrographic and behavioral seihippocampus and cortex of all DKI mice we examined. This sugzures in some, but not all, mice of both genotypes. These data
gests that, in the absence of APP overexpression, A␤ overproducdemonstrate that spontaneous electrographic hyperactivity does
tion is not sufficient to alter network excitability and lends
not automatically predispose the network to chemically induced
further support to the hypothesis that full-length APP or another
seizures and suggests that the two neurotransmitter systems may
cleavage fragment underlies EEG abnormalities in the tet-off APP
be differentially altered by APP overexpression.
animals.
We were next curious to test whether allaying spontaneous
EEG abnormalities in the tet-off APP mice would normalize their
Increased susceptibility to chemically induced seizures is not
susceptibility to picrotoxin. We treated 6-month-old APP/TTA
attenuated by diminishing spontaneous hyperactivity
mice with DOX for 5 weeks before implanting them with transBecause the tet-off APP mice exhibit spontaneous EEG abnormalimitters and challenging them with picrotoxin. Despite the exties, we wanted to test whether they were also more vulnerable to
pected decline in SWD frequency, the DOX-treated APP/TTA
chemically induced seizures, as demonstrated for other APPmice were still significantly more susceptible to picrotoxin than
transgenic models (Del Vecchio et al., 2004; Palop et al., 2007;
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layer 2/3 was not significantly altered by transgene expression or treatment.
Changes in vGAT staining were opposite to those in vGLUT. In layer 5, the area
of vGAT staining increased with APP
overexpression ( p ⬍ 0.01 vs control) but
decreased to control levels after transgene
suppression. vGAT staining in layer 2/3
showed a similar pattern: although the increase in vGAT with transgene expression
was not significant, the drop after suppression was ( p ⬍ 0.01 vs untreated).
vGAT levels after GSI treatment fell in between those of untreated and DOXtreated animals, but were not significantly
changed from untreated APP/TTA mice.
Together, these analyses revealed
that continued overexpression of APP
caused a significant reduction in the ratio of vGLUT:vGAT within layer 5 ( p ⬍
0.01 vs control) and a parallel trend in
layer 2/3. Transgene suppression restored the excitatory/inhibitory ratio to
control levels, whereas GSI treatment
did not.
Suppression of APP overexpression
during postnatal development delays
the onset of EEG abnormalities in APP/
TTA mice
Our EEG recordings after transgene
suppression suggested that spontaneous
SWDs were dependent on continued exFigure 6. APP/TTA and control mice were challenged with kainic acid (A, C, D, E) or picrotoxin (B, F, G, H ) and scored for seizure pression of mutant APP, but told us litinduction by EEG and behavioral observation. A separate cohort was treated with DOX for 5 weeks before picrotoxin challenge tle about how network hyperexcitability
(I–K ). A, B, Example EEG traces from APP/TTA mice challenged with kainic acid or picrotoxin. Scale bars: A, 0.4 mV, 1 s; B, 0.4 mV, arose in the first place. Our past studies
5 s. C, F, I, Seizure severity was scored using a modified Racine scale. D, G, J, Latency to first seizure. E, H, K, Total number of seizures with the tet-off mice demonstrated that
observed in the first hour after drug challenge. *p ⬍ 0.05, **p ⬍ 0.01, ***p ⬍ 0.001.
APP overexpression during postnatal
brain development had a lifelong impact on locomotor hyperactivity (Rodgers et al., 2012). To test whether delaying the expression of
similarly treated controls by every metric we tested ( p ⬍ 0.05,
Student’s t test, n ⫽ 5–7 mice/genotype). These data suggest that
transgenic APP might also prevent network hyperexcitability,
increased sensitivity to acute GABA inhibition is mechanistically
we reared a naive cohort of APP/TTA and control mice on
distinct from spontaneous SWDs and that cellular changes that
DOX from postnatal day 2 (P2) until P42 to withhold APP
diminish the likelihood of spontaneous SWDs are insufficient to
overexpression until the brain was fully developed. At 6 weeks
protect against induced seizure.
of age (P42), the mice were switched to normal chow to activate expression of transgenic APP (Fig. 8). At times ranging
from 1 to 9 months later, we implanted the mice with EEG
APP overexpression alters the excitatory to inhibitory balance
transmitters and recorded baseline cortical activity. We were
in the cortex
thus able to compare the appearance of EEG abnormalities in
The sensitivity of APP/TTA mice to both spontaneous SWDs and
juvenile- and adult-onset mice that were matched for duration of
acute GABAergic inhibition prompted us to test whether there may
transgenic APP expression. Although the juvenile-onset APP/TTA
be underlying changes in the excitatory to inhibitory balance. We
mice showed higher-than-normal SWD frequency from the earliest
examined the relative levels of glutamatergic to GABAergic innervaages we could examine (3 months), the adult-onset mice displayed
tion by measuring the density of synaptic immunostaining for their
no EEG abnormalities after 1, 3, or 6 months of transgene expresrespective vesicular neurotransmitter transporters, vGLUT and
sion. However, by 9 months of APP overexpression, SWD frequency
vGAT. Because our EEG recordings were taken above parietal corrose dramatically, reaching rates similar to those observed in
tex, we focused our histological analyses on this region and specifijuvenile-onset animals (n ⫽ 5–11 mice/treatment/age; Fig. 8). Decally on the main neuronal cell body layers 2/3 and 5. Within layer 5,
spite the initial protection afforded by delaying APP exposure, these
the area occupied by vGLUT staining was significantly lower in APP/
mice ultimately developed EEG abnormalities that were as severe as
TTA mice than in controls (p ⬍ 0.05; n ⫽ 4 –5 mice/group; Fig. 7).
vGLUT density was restored to control levels by 4 –5 weeks of transthose in animals exposed to transgenic APP as juveniles. The congene suppression, but was not rescued by GSI treatment, which is
trast between the early appearance of SWDs in juvenile-onset mice
consistent with our EEG findings. In contrast, vGLUT staining within
and the substantial delay of SWDs in adult-onset animals suggests
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Figure 7. Transgene suppression restores cortical markers of glutamatergic and GABAergic innervation to control levels. A, Tissue from TTA and APP/TTA mice used for EEG recording was coimmunostained
forvGLUT1andvGAT.Imagesshowcortexlayer5fromuntreatedTTA(control)micealongwithuntreated,DOX-treated,andGSI-treatedAPP/TTAmice.Scalebar,50 m.B,PercentareaoccupiedbyvGLUT1and
vGAT staining within layers 2/3 and 5 was measured using a custom MATLAB script. Untreated APP/TTA mice had a lower density of vGLUT1 and higher density of vGAT in layer 5 than control animals, with a
similar trend in layer 2/3. Transgene suppression restored these excitatory/inhibitory markers to control levels, whereas GSI had no effect. *p ⬍ 0.05, **p ⬍ 0.01.

Figure 8. Delaying the onset of APP overexpression protects against early EEG abnormalities. A, EEG activity was compared between juvenile-onset mice that express transgenic APP from birth
and adult-onset mice in which APP overexpression was delayed with DOX until the mice reached 6 weeks of age. B, SWDs were common in juvenile-onset APP/TTA mice at both 6 and 9 months of
age, but were found in adult-onset mice only after 9 months of APP overexpression. Scale bar, 0.4 mV, 5 s. C, Transgenic APP expression from birth resulted in elevated SWD frequency by the earliest
ages we could examine (3 months), whereas mice with delayed transgene expression develop SWDs considerably later (9 months). Filled circles, juvenile onset; open circles, adult onset. D, After 9
months of APP overexpression, adult onset mice were treated either with DOX or with GSI for 5 weeks. The frequency of SWDs decreased to control levels within 2 weeks of transgene suppression,
but did not change significantly with secretase inhibition. Filled circles, DOX; open circles, GSI. *p ⬍ 0.05, **p ⬍ 0.01.

that postponing transgenic APP expression either provides initial,
but not indefinite, protection from mutant APP and its cleavage
products or that the two models may reach the same phenotype by
distinct mechanisms.

We next examined whether SWDs, once present, were dependent on continued APP overexpression in adult-onset mice, as
they had been in mice that expressed APP from birth. After completing baseline EEG recordings in adult-onset mice that had
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overexpressed APP for 9 months, we started DOX treatment and
continued weekly recording. We found that SWD frequency decreased to rates that were statistically indistinguishable from controls within 2 weeks of transgene suppression ( p ⬎ 0.05, n ⫽ 5–9
mice/genotype; Fig. 8). We further tested whether selective reduction of soluble A␤ could abate SWDs by treating adult-onset
mice with GSI. However, similar to our findings in juvenile-onset
mice, GSI treatment had no effect on SWD frequency ( p ⬎ 0.05;
n ⫽ 3 mice; Fig. 8). This finding suggests that, regardless of when
they appear, network changes that support spontaneous SWDs
are actively maintained by the continued overexpression of APP
rather than by the overproduction of A␤.

Discussion
We set out to distinguish whether soluble A␤, deposited amyloid,
or APP itself was responsible for the epileptiform phenotype reported in transgenic models of Alzheimer’s disease. In the process, we discovered that the cause of network hyperexcitability
was more complex than we expected and was not due directly to
either A␤ or amyloid. We found that juvenile APP overexpression predisposed the adult brain to hypersynchronous discharge.
Delaying APP overexpression for just 6 weeks protected against
epileptiform activity for ⬎6 months, but spontaneous hyperexcitability ultimately emerged as amyloid pathology became severe. Surprisingly, whether epileptiform events were provoked by
the development or degeneration, plaques themselves do not appear to govern network activity. Instead, we find that APP itself— or one of its processed fragments— determines the
persistence of hyperactivity. Reducing the level of transgenic
APP, but not that of A␤, restored network activity to normal even
while significant amyloid pathology remained. Phenotypic rescue took longer than was needed to arrest transgene expression,
suggesting that APP overexpression elicited network alterations
through an indirect mechanism. Consistent with this idea, markers of excitatory and inhibitory innervation revealed an imbalance in the cortical network that supported EEG abnormalities
but was restored to normal after APP suppression.
Our study is the first to test directly the proposed link between
soluble A␤ species and seizures (Palop and Mucke, 2010). In
contrast to what we had expected, diminishing A␤ with GSI failed
to reduce the frequency of SWDs. One concern we had in interpreting these data was that GSI treatment failed to completely
eliminate soluble A␤ from the brain, raising the possibility that
the residual A␤ was sufficient to maintain SWDs. However,
transgene suppression was less efficient at lowering soluble A␤
than GSI yet fully suppressed the SWD phenotype, arguing
against this explanation. Instead, our findings suggest that A␤ is
not the primary cause of epileptiform discharge in APP-transgenic
models. This conclusion is further supported by the absence of EEG
abnormalities in aged APP/PS1 knock-in mice with elevated A␤ production and late-onset plaque formation. Together, these findings
suggest that other fragments, or even full-length APP itself, may be
responsible for network disruption in APP-transgenic models. APP
overexpression might promote network hyperexcitability by exacerbating a physiological function of the endogenous protein, such as
neurogenesis, neurite outgrowth, or synapse formation (Zheng and
Koo, 2011; Hoe et al., 2012). Endogenous APP expression is highest
during synaptogenesis between 2 and 6 weeks of age (Hoe et al.,
2012; Westmark, 2013), a time that may be when the developing
network is the most sensitive to APP overexpression. Consistent
with this idea, we find that mice exposed to transgenic APP as juveniles developed epileptiform activity much earlier than animals in
which APP expression was delayed until adulthood. This result sug-
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gests that APP overexpression during postnatal development makes
the brain more susceptible to hypersynchronous activity in the adult.
Although juvenile APP exposure was sufficient to prime network hyperactivity, continued APP overexpression was necessary
to maintain it. Intriguingly, even though transgenic APP was
reduced by 80% within days of DOX treatment, it took several
weeks for SWD frequency to fully decline. The temporal disparity
suggests that the mechanism supporting spontaneous discharge
is not a simple on/off process. Our histological data suggest that
APP overexpression alters the pattern of cortical innervation,
although it is unclear whether it acts directly on synapse formation during development or indirectly as a consequence of later
neuronal hyperactivity. The direction of this shift, toward elevated GABAergic and diminished glutamateric innervation, intuitively contradicts the observed hypersynchronous phenotype;
however, past work has shown that increased GABAergic signaling can synchronize neuronal firing in the cortex and trigger
epileptiform activity (Cobb et al., 1995; Klaassen et al., 2006).
Alternatively, the shift in innervation may be a compensatory
attempt to dampen network hyperactivity caused by APP overexpression (Palop et al., 2007). Whether causal or reactive, the
levels of GABAergic and glutamatergic innervation returned to
control levels once transgenic APP was removed from the system.
The level of APP expression may thus act as a rheostat on synaptic
balance in the brain.
Although spontaneous discharge eventually subsided after
APP suppression, bigenic mice remained susceptible to chemically induced seizures. APP/TTA mice were more sensitive to
picrotoxin than controls regardless of whether APP expression
was active or not, suggesting that some aspects of the network
may remain permanently altered by juvenile APP exposure. Past
studies in other APP-transgenic models have identified a similar
vulnerability to pentylenetetrazol (Del Vecchio et al., 2004; Palop
et al., 2007; Westmark et al., 2008; Roberson et al., 2011). Intriguingly, APP/TTA mice were identical to controls for kainate susceptibility, revealing an unexpected degree of selectivity in seizure
sensitivity. Recent work suggests that tonic hyperpolarization of
cortical interneurons contribute to network excitability in J20
mice (Verret et al., 2012), whereas other APP-transgenic models
display overt degeneration of inhibitory neurons (Ramos et al.,
2006; Baglietto-Vargas et al., 2010; Takahashi et al., 2010; Loreth
et al., 2012). Together, these results support a permanent reduction in GABAergic function caused by developmental exposure
to APP overexpression.
How could it be that some aspects of GABAergic dysfunction
remain amenable to APP suppression, whereas other changes
were permanent? Our experiments do not speak to this distinction directly, but we may gain insight from comparing the phenotypes that changed with those that did not. Both SWD and the
theta/delta imbalance were abated by reducing APP levels, but
increased sensitivity to picrotoxin was not. Parvalbumin-positive
interneurons have been linked to the spontaneous EEG features
in APP-transgenic mice and are believed to drive theta oscillations in the healthy brain (Hangya et al., 2009; Cutsuridis and
Hasselmo, 2012; Verret et al., 2012). In contrast, other classes of
GABAergic interneurons appear to be involved in synchronous
discharge caused by picrotoxin (Hiscock et al., 1996). This raises
the possibility that APP exposure may have distinct consequences
on different classes of interneurons depending on when the
transgene is expressed.
The final experiment of our study demonstrated that the timing of APP expression has a significant impact on the resulting
phenotype. We had shown previously that postponing transgenic

Born et al. • APP Suppression Rescues EEG Abnormalities

3838 • J. Neurosci., March 12, 2014 • 34(11):3826 –3840

APP expression until 6 weeks of age attenuated locomotor hyperactivity in the adult (Rodgers et al., 2012). Here, we show that
postponing transgene expression also delayed the appearance of
EEG abnormalities. Ultimately, the adult-onset mice developed
SWDs similar to those seen at earlier ages after juvenile APP
expression, but only after severe amyloid accumulation. This disparity suggests there may be two ways to reach the same phenotypic outcome. In one case, APP overexpression during postnatal
development alters network formation to favor hyperexcitability;
in the other, pathological damage degrades the network to a point
where it becomes vulnerable to synchronization. In both settings,
SWDs only persist as long as APP overexpression continues. We
therefore propose a “two-hit” model in which either developmental alterations or pathological damage make cortical circuits
permissive for synchrony, but then require APP overexpression
to trigger recurrent SWDs. From our experiments, we cannot
identify the precise fragment responsible, but our GSI findings
rule out AICD, P3, CTF␣, and CTF␤, because all four would be
affected by the loss of ␥-processing. Although our data do not
speak to the mechanism by which APP overexpression triggers
SWDs, past work in other models suggest a possible explanation.
In particular, BACE1-null mice display seizure abnormalities
similar to those described in APP-transgenic mice (Kobayashi et
al., 2008; Hitt et al., 2010; Hu et al., 2010). Moreover, expression
of mutant APP on the BACE-null background exacerbates the
seizure phenotype (Kobayashi et al., 2008), which suggests that
neither sAPP␤ nor CTF␤ contribute to SWDs in APP/TTA mice.
Instead, high levels of full-length APP in the transgenic mice may
commandeer a disproportionate fraction of the cell’s limited
BACE pool, thereby reducing its ability to process other substrates critical for neuronal function. BACE normally cleaves several proteins involved in regulating neuronal activity, including
the accessory subunits for voltage-gated ion channels and neuregulin, both of which play important roles in GABAergic neurons (Wong et al., 2005; Kim et al., 2007; Kim et al., 2011; Fleck et
al., 2012; Sachse et al., 2013). NaV␤2 controls membrane localization of the sodium channel NaV1.1 to facilitate electrical excitability (Kovacs et al., 2010; Huth and Alzheimer, 2012),
whereas neuregulin 1 stimulates GABA release (Wen et al., 2010).
Reduction of either protein promotes epileptogenesis (Yu et al.,
2006; Cheah et al., 2012; Tan et al., 2012). With multiple activityregulating proteins dependent on BACE processing, any process
that impairs this function could alter the normal balance of excitability in the brain.
Our findings may also offer a new perspective on the association between seizures and AD in the clinical literature. Epidemiological studies have revealed that seizure risk is increased 87-fold
in patients with early-onset AD (Amatniek et al., 2006). Seizure
risk in patients with late-onset AD drops to only threefold, offset
in part because seizure risk for the entire population increases
with age. The risk disparity suggests that there may be different
mechanisms underlying the predisposition for seizure in each
population. Inherited mutations may exert A␤-independent effects during circuit formation that predispose the network to
hypersynchrony. Absent this developmental influence, patients
with late-onset disease may be more resistant to seizures until the
network becomes severely damaged. In both cases, lowering A␤
may alleviate the pathological and cognitive progression of AD,
but our data suggest that this peptide may be the wrong target for
alleviating hypersynchrony.
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Köhler C, Ebert U, Baumann K, Schroder H (2005) Alzheimer’s disease-like
neuropathology of gene-targeted APP-SLxPS1mut mice expressing the
amyloid precursor protein at endogenous levels. Neurobiol Dis 20:528 –
540. CrossRef Medline
Kovacs DM, Gersbacher MT, Kim DY (2010) Alzheimer’s secretases regulate voltage-gated sodium channels. Neurosci Lett 486:68 –72. CrossRef
Medline
Lalonde R, Dumont M, Staufenbiel M, Strazielle C (2005) Neurobehavioral
characterization of APP23 transgenic mice with the SHIRPA primary
screen. Behav Brain Res 157:91–98. CrossRef Medline
Larner AJ, Doran M (2006) Clinical phenotypic heterogeneity of Alzhei-

J. Neurosci., March 12, 2014 • 34(11):3826 –3840 • 3839
mer’s disease associated with mutations of the presenilin-1 gene. J Neurol
253:139 –158. CrossRef Medline
Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy
MP, Golde TE (2006a) Anti-A␤42- and anti-A␤40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin
Invest 116:193–201. CrossRef Medline
Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, Kim J,
McGowan E, Reed DK, Rosenberry TL, Das P, Golde TE (2006b) Insights into the mechanisms of action of anti-A␤ antibodies in Alzheimer’s
disease mouse models. FASEB J 20:2576 –2578. CrossRef Medline
Loreth D, Ozmen L, Revel FG, Knoflach F, Wetzel P, Frotscher M, Metzger F,
Kretz O (2012) Selective degeneration of septal and hippocampal
GABAergic neurons in a mouse model of amyloidosis and tauopathy.
Neurobiol Dis 47:1–12. CrossRef Medline
Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER (1996)
Control of memory formation through regulated expression of a CaMKII
transgene. Science 274:1678 –1683. CrossRef Medline
Menéndez M (2005) Down syndrome, Alzheimer’s disease and seizures.
Brain Dev 27:246 –252. CrossRef Medline
Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fülöp L,
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